CN102548557B - 用于降低β-淀粉状蛋白生成的化合物 - Google Patents

用于降低β-淀粉状蛋白生成的化合物 Download PDF

Info

Publication number
CN102548557B
CN102548557B CN201080043469.3A CN201080043469A CN102548557B CN 102548557 B CN102548557 B CN 102548557B CN 201080043469 A CN201080043469 A CN 201080043469A CN 102548557 B CN102548557 B CN 102548557B
Authority
CN
China
Prior art keywords
dihydro
pyrimidine
chloro
pyrano
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080043469.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102548557A (zh
Inventor
K·M·博伊
J·M·盖尔农
J·E·马科
R·E·奥尔森
施建良
L·A·汤普森三世
邬永金
徐力
张云惠
D·S·策夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN102548557A publication Critical patent/CN102548557A/zh
Application granted granted Critical
Publication of CN102548557B publication Critical patent/CN102548557B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201080043469.3A 2009-07-31 2010-07-28 用于降低β-淀粉状蛋白生成的化合物 Expired - Fee Related CN102548557B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US23020209P 2009-07-31 2009-07-31
US61/230,202 2009-07-31
US61/230202 2009-07-31
US32420110P 2010-04-14 2010-04-14
US61/324201 2010-04-14
US61/324,201 2010-04-14
PCT/US2010/043487 WO2011014535A1 (en) 2009-07-31 2010-07-28 COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION

Publications (2)

Publication Number Publication Date
CN102548557A CN102548557A (zh) 2012-07-04
CN102548557B true CN102548557B (zh) 2014-12-24

Family

ID=43066942

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080043469.3A Expired - Fee Related CN102548557B (zh) 2009-07-31 2010-07-28 用于降低β-淀粉状蛋白生成的化合物

Country Status (28)

Country Link
US (4) US8486952B2 (enExample)
EP (1) EP2459197B1 (enExample)
JP (1) JP5680082B2 (enExample)
KR (1) KR20140015126A (enExample)
CN (1) CN102548557B (enExample)
AR (1) AR077434A1 (enExample)
AU (1) AU2010279019B2 (enExample)
BR (1) BR112012002270A2 (enExample)
CA (1) CA2766515A1 (enExample)
CO (1) CO6430430A2 (enExample)
DK (1) DK2459197T3 (enExample)
EA (1) EA020322B1 (enExample)
ES (1) ES2554327T3 (enExample)
HR (1) HRP20151133T1 (enExample)
HU (1) HUE026705T2 (enExample)
IL (1) IL217173A (enExample)
MX (1) MX2012000973A (enExample)
MY (1) MY156274A (enExample)
NZ (1) NZ597701A (enExample)
PE (1) PE20120897A1 (enExample)
PL (1) PL2459197T3 (enExample)
PT (1) PT2459197E (enExample)
SG (1) SG177526A1 (enExample)
SI (1) SI2459197T1 (enExample)
SM (1) SMT201600011B (enExample)
TW (1) TWI468402B (enExample)
WO (1) WO2011014535A1 (enExample)
ZA (1) ZA201200409B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010099279A1 (en) * 2009-02-27 2010-09-02 Dow Agrosciences Llc N-alkoxyamides of 6-(substituted phenyl)-4-aminopicolinates and 2-(substituted phenyl)-6-amino-4-pyrimidinecarboxylates and their use as selective herbicides for crops
MX2013002511A (es) 2010-09-02 2013-07-29 Takeda Pharmaceutical Triazoles fusionados para el tratamiento o profilaxis de daño cognitivo moderado.
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
TW201309655A (zh) * 2011-01-28 2013-03-01 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
PH12013502033A1 (en) 2011-04-08 2014-01-06 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
US9206195B2 (en) 2011-08-09 2015-12-08 Boehringer Ingelheim International Gmbh Dihydrothienopyrimidines
EP2776439B1 (en) 2011-11-09 2018-07-04 Janssen Sciences Ireland UC Purine derivatives for the treatment of viral infections
DK2812331T3 (en) 2012-02-08 2019-04-08 Janssen Sciences Ireland Unlimited Co PIPERIDINOPYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
UA125503C2 (uk) 2012-06-13 2022-04-13 Інсайт Холдинґс Корпорейшн Заміщені трициклічні сполуки як інгібітори fgfr
WO2014009509A1 (en) 2012-07-13 2014-01-16 Janssen R&D Ireland Macrocyclic purines for the treatment of viral infections
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9499549B2 (en) 2012-10-10 2016-11-22 Janssen Sciences Ireland Uc Pyrrolo[3,2-]pyrimidine derivatives for the treatment of viral infections and other diseases
UA118341C2 (uk) 2012-11-16 2019-01-10 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Гетероциклічні заміщені похідні 2-амінохіназоліну для лікування вірусних інфекцій
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
JP6072308B2 (ja) 2013-02-21 2017-02-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノンｉｉ
UA118751C2 (uk) 2013-02-21 2019-03-11 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Похідні 2-амінопіримідину для лікування вірусних інфекцій
EP2958919B1 (en) 2013-02-21 2019-05-22 Boehringer Ingelheim International GmbH Dihydropteridinones i
BR112015024411B1 (pt) 2013-03-29 2022-02-22 Janssen Sciences Ireland Uc Desaza-purinonas macrocíclicas para o tratamento de infeções virais e composição farmacêutica que os compreende
MY181497A (en) 2013-04-19 2020-12-23 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
AU2014270418B2 (en) 2013-05-24 2017-11-30 Janssen Sciences Ireland Uc Pyridone derivatives for the treatment of viral infections and further diseases
WO2014195321A1 (en) 2013-06-04 2014-12-11 Acturum Life Science AB Triazole compounds and their use as gamma secretase modulators
DK3004080T3 (da) 2013-06-04 2019-01-02 Acturum Real Estate Ab Triazolforbindelser og deres anvendelse som gamma-sekretase-modulatorer
JP6368777B2 (ja) 2013-06-04 2018-08-01 アクチュラム・ライフ・サイエンス・アクチエボラーグ ピリミジン化合物およびガンマセクレターゼモジュレーターとしてのその使用
KR101499329B1 (ko) * 2013-06-17 2015-03-06 주식회사 대웅제약 (2-(3,4-다이메톡시페닐)-5-(3-메톡시프로필)벤조퓨란)의결정형 및 이의 제조방법
NO3030563T3 (enExample) 2013-06-27 2018-01-06
CA2913691C (en) 2013-07-30 2022-01-25 Janssen Sciences Ireland Uc Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
WO2015107053A1 (en) * 2014-01-20 2015-07-23 F. Hoffmann-La Roche Ag N-phenyl-lactam derivatives capable of stimulating neurogenesis and their use in the treatment of neurological disorders
EP3126355A1 (en) * 2014-04-02 2017-02-08 Bristol-Myers Squibb Company Difluoromethoxy compound with low bioactivation potential for the reduction of beta-amyloid production
CN105272975B (zh) * 2014-06-10 2019-03-26 中国科学院上海药物研究所 一类具有1,2,4-恶二唑片段结构的吲哚生物碱及其制备方法和用途
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CR20170390A (es) 2015-02-20 2017-10-23 Incyte Holdings Corp Heterociclos biciclicos como inhibidores de fgfr
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
KR102591886B1 (ko) * 2015-07-21 2023-10-20 광저우 맥시노벨 파마수티컬스 씨오., 엘티디. 축합고리 피리미딘계 화합물, 중간체, 이의 제조 방법, 조성물 및 응용
BR112018008714A2 (pt) 2015-10-29 2018-10-30 Effector Therapeutics Inc inibidores de isoindolina, azaisoindolina, dihidroindenona e dihidroazaindenona da mnk1 e mnk2
CN108602814A (zh) 2015-10-29 2018-09-28 效应治疗股份有限公司 抑制mnk1和mnk2的吡咯并-、吡唑并-、咪唑并-嘧啶和吡啶化合物
WO2017087808A1 (en) 2015-11-20 2017-05-26 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
CN109476675B (zh) 2016-07-01 2022-12-09 爱尔兰詹森科学公司 用于治疗病毒性感染的二氢吡喃并嘧啶衍生物
AU2017335205B2 (en) 2016-09-29 2021-11-04 Janssen Sciences Ireland Unlimited Company Pyrimidine prodrugs for the treatment of viral infections and further diseases
MX394700B (es) 2017-02-14 2025-03-24 Effector Therapeutics Inc Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos.
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
JP7335242B2 (ja) * 2017-11-27 2023-08-29 エフ． ホフマン－ラ ロシュ アーゲー ピリミジン誘導体
WO2019164861A1 (en) 2018-02-21 2019-08-29 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
TW202415645A (zh) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
BR112020022392A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
PE20210919A1 (es) 2018-05-04 2021-05-19 Incyte Corp Sales de un inhibidor de fgfr
KR20210102211A (ko) 2018-10-24 2021-08-19 이펙터 테라퓨틱스, 인크. Mnk 억제제의 결정질 형태
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
PE20221504A1 (es) 2019-12-04 2022-09-30 Incyte Corp Derivados de un inhibidor de fgfr
JP7720840B2 (ja) 2019-12-04 2025-08-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
TW202313611A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008136756A1 (en) * 2007-05-08 2008-11-13 Astrazeneca Ab Pyrrolopyrimidin-7-one derivatives and their use as pharmaceuticals
WO2009087127A1 (en) * 2008-01-11 2009-07-16 F. Hoffmann-La Roche Ag Modulators for amyloid beta

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE346064T1 (de) * 2000-09-15 2006-12-15 Vertex Pharma Pyrazolverbindungen als protein-kinasehemmer
WO2002068415A1 (en) * 2000-12-21 2002-09-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2009020580A1 (en) * 2007-08-06 2009-02-12 Schering Corporation Gamma secretase modulators
WO2009045314A1 (en) * 2007-09-28 2009-04-09 Schering Corporation Gamma secretase modulators
WO2009073779A1 (en) * 2007-12-06 2009-06-11 Schering Corporation Gamma secretase modulators
JP2011506335A (ja) * 2007-12-06 2011-03-03 シェーリング コーポレイション γ−セクレターゼ調節剤
EP2268636A1 (en) * 2007-12-11 2011-01-05 Schering Corporation Gamma secretase modulators
CA2708300A1 (en) * 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
EP2257541B1 (en) * 2008-02-22 2013-08-14 F. Hoffmann-La Roche AG Modulators for amyloid beta
CA2736924C (en) 2008-10-09 2016-06-28 F. Hoffmann-La Roche Ag Modulators for amyloid beta
MX2011004680A (es) * 2008-11-06 2011-05-25 Astrazeneca Ab Moduladores de beta amiloide.
WO2010088414A2 (en) 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor potentiators for the treatment of neurological conditions
UY32622A (es) 2009-05-12 2010-12-31 Astrazeneca Ab Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)
ES2519565T3 (es) 2009-07-15 2014-11-07 Janssen Pharmaceuticals Inc. Derivados de triazol e imidazol sustituidos como moduladores de gamma secretasa

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008136756A1 (en) * 2007-05-08 2008-11-13 Astrazeneca Ab Pyrrolopyrimidin-7-one derivatives and their use as pharmaceuticals
WO2009087127A1 (en) * 2008-01-11 2009-07-16 F. Hoffmann-La Roche Ag Modulators for amyloid beta

Also Published As

Publication number Publication date
TW201107311A (en) 2011-03-01
CO6430430A2 (es) 2012-04-30
EP2459197A1 (en) 2012-06-06
SI2459197T1 (sl) 2015-12-31
EA201270225A1 (ru) 2012-07-30
PT2459197E (pt) 2015-12-18
DK2459197T3 (en) 2016-01-25
MX2012000973A (es) 2012-03-06
BR112012002270A2 (pt) 2016-06-14
HRP20151133T1 (hr) 2015-11-20
US20150336975A1 (en) 2015-11-26
US8486952B2 (en) 2013-07-16
PL2459197T3 (pl) 2016-04-29
JP5680082B2 (ja) 2015-03-04
IL217173A0 (en) 2012-02-29
AU2010279019B2 (en) 2014-12-18
EP2459197B1 (en) 2015-10-14
US20130178462A1 (en) 2013-07-11
US20110212937A1 (en) 2011-09-01
MY156274A (en) 2016-01-29
SMT201600011B (it) 2016-02-25
TWI468402B (zh) 2015-01-11
EA020322B1 (ru) 2014-10-30
SG177526A1 (en) 2012-02-28
CA2766515A1 (en) 2011-02-03
AU2010279019A1 (en) 2012-02-09
CN102548557A (zh) 2012-07-04
US20150152089A1 (en) 2015-06-04
AR077434A1 (es) 2011-08-24
ZA201200409B (en) 2013-06-26
HK1164732A1 (zh) 2012-09-28
IL217173A (en) 2016-05-31
WO2011014535A1 (en) 2011-02-03
HUE026705T2 (en) 2016-07-28
KR20140015126A (ko) 2014-02-06
ES2554327T3 (es) 2015-12-18
PE20120897A1 (es) 2012-07-23
NZ597701A (en) 2012-12-21
JP2013500975A (ja) 2013-01-10

Similar Documents

Publication Publication Date Title
CN102548557B (zh) 用于降低β-淀粉状蛋白生成的化合物
CN104470925B (zh) 作为激酶抑制剂的咪唑并三嗪甲腈
CN105829315B (zh) 可用作Wee-1激酶抑制剂的嘧啶并嘧啶酮类
TWI719949B (zh) 稠合五環咪唑衍生物
CN104812762B (zh) 取代的环状嘧啶和三嗪以及它们的用途
TWI480282B (zh) 稠合雜環衍生物及其用途
CN105939997B (zh) 作为dlk抑制剂的吡唑衍生物及其用途
US8637525B2 (en) Compounds for the reduction of beta-amyloid production
JP2022548822A (ja) がんの治療における使用のためのヘテロ環式化合物
TWI726888B (zh) 核受體調節劑
TWI596095B (zh) Dihydropyridazine-3,5-dione derivatives
CN110088096A (zh) 作为泛素特异性蛋白酶7的抑制剂的哌啶衍生物
TW201722933A (zh) 苯內醯胺化合物
TW201602100A (zh) 選擇性經取代之喹啉化合物
JP2017518276A (ja) ブルトン型チロシンキナーゼ（ｂｔｋ）インヒビターとしての多フルオロ置換化合物
CN110003178A (zh) 二杂芳基化合物及其用途
CN103328451B (zh) 降低β-淀粉样物质生成的化合物
TW201706258A (zh) 作為ｔｎｆ信號傳遞調節劑之吲唑酮
KR20240026911A (ko) 골수성 세포 2 작용제 상에서 발현되는 유발 수용체로서의 헤테로고리 화합물 및 사용 방법
CN116096719A (zh) 作为alk5抑制剂的哒嗪基氨基衍生物
CN101981031A (zh) 具有促肾上腺皮质激素释放因子拮抗活性的三环化合物和含有它们的药物组合物
CN102171220A (zh) 用作CRF1拮抗剂的吡唑并[5,1-b]唑衍生物
CN107207521A (zh) 作为沉默调节蛋白调节剂的取代的桥连脲类似物
CN107072993B (zh) 含有钠依赖性磷酸转运蛋白抑制剂的药物
CN112135818A (zh) 4-羟基哌啶衍生物及其作为泛素特异性蛋白酶19(usp19)的抑制剂的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141224

Termination date: 20190728

CF01 Termination of patent right due to non-payment of annual fee